Daiichi Sankyo’s new drug for the treatment of AML receives FDA priority channel
ADC评论
October 25, 2022
On October 24, the Japanese pharmaceutical company Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA)
